Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

2 Most will agree that these goals are probably achieved best by normalizing secretion of growth hormone and insulin-like growth factor 1 (IGF-1) and that the sequelae of acromegaly are serious ...

Causes: Acromegaly occurs when the pituitary gland, a small hormone-making structure in the brain, produces too much growth hormone for a long period of time. This hormone normally regulates the ...

The typical Sandostatin dosage for adults with acromegaly is as follows ... They will monitor your GH or IGF-1 levels every 2 weeks. Dosage adjustments: If needed, your doctor may increase ...

Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone. The PATHFNDR-2 study is evaluating ...

A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release. Adults diagnosed with endogenous Cushing’s syndrome have a higher ...

ProBioGen and Marea Therapeutics Inc. have successfully completed a sprint project to deliver clinical material for MAR002.

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...